Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 16, 2026Score 13/30231% above fair value
$116.35+4.35 (+3.88%)
Close on Nov 18, 2026Market cap $7.30BP/E –Yield –
Twist Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Twist Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$144.98M. For fiscal 2025 it was -$136.26M. The highest annual figure on record is -$58.48M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$136.26M | – |
| FY2024 | Sep 30, 2024 | -$220.83M | – |
| FY2023 | Sep 30, 2023 | -$217.16M | – |
| FY2022 | Sep 30, 2022 | -$234.78M | – |
| FY2021 | Sep 30, 2021 | -$152.73M | – |
| FY2020 | Sep 30, 2020 | -$140.08M | – |
| FY2019 | Sep 30, 2019 | -$108.85M | – |
| FY2018 | Sep 30, 2018 | -$70.56M | – |
| FY2017 | Sep 30, 2017 | -$58.48M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$36.28M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$45.86M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$32.90M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$29.93M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$30.12M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$41.56M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$34.64M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$36.04M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$88.92M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$48.89M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$46.98M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$50.11M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$60.78M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$61.64M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$44.63M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$56.87M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$61.16M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$60.80M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$55.94M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$39.81M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$42.12M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$38.00M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$32.79M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$23.97M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$28.20M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$32.09M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$55.83M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$31.57M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$28.12M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$26.26M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$22.90M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$19.70M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$17.49M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$16.62M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$16.75M | – |
See a number that looks wrong?